- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04654910
PROMIS and Patient Satisfaction
April 7, 2023 updated by: Judy Baumhauer, MD, University of Rochester
Does Patient-Reported Outcome Measure Use in Clinic Visits Improve Patient Satisfaction and Experience? A Randomized, Controlled Trial
The primary aim for this study is to determine if patient satisfaction and experience is improved with the active discussion/inclusion of PROMIS scores during new foot and ankle clinic patient visits.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
275
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Rochester, New York, United States, 14618
- University of Rochester Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion
- Patients over the age of 18
- New patient at the foot and ankle clinic
Exclusion
- Patients under the age of 18
- Patients presenting for a Follow up visit
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Control
enrolled subjects that do NOT receive explanation of PROMIS measures during visit.
|
Subjects will complete the PROMIS assessment but will not receive an explanation of the tool.
|
Active Comparator: Intervention
enrolled subjects that DO receive explanation of PROMIS measures during visit.
|
The surgeon completing the clinical visit with the participant will explain what the PROMIS tool is, the purpose of the tool and what the participant's scores mean using a script.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
mean pain interference domain measured by PROMIS
Time Frame: baseline, before intervention
|
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children.
It can be used with the general population and with individuals living with chronic conditions.
Scores are typically between 20-80, but may be 0-100.
Any result with higher a higher number is indicating higher pain interference effect.
|
baseline, before intervention
|
mean Patient Activation Measure (PAM)
Time Frame: baseline, after intervention
|
Our primary outcome measure is the Patient Activation Measure (PAM).
The PAM is a 13-item scale with a 5-point Likert response scale for all questions.
Raw scores are scaled to a range of 0-100 with 100 being the highest activation in self- management.
|
baseline, after intervention
|
percent of participant who respond favorably on the Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS)
Time Frame: baseline, after intervention
|
We will assess scores on the Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey.
This is a standardized tool to measure patients' perception of care provided by physicians in an office setting.
Specifically, for our analysis will we focus specifically on the individual question to assess communication.
We will compare the percentage of participants in the intervention versus control group who respond favorably to this question using a chi-square test of association.
|
baseline, after intervention
|
mean depression
Time Frame: baseline, before intervention
|
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children.
It can be used with the general population and with individuals living with chronic conditions.
Scores are typically between 20-80, but may be 0-100.
Any result with higher a higher number is indicating higher depression effect.
|
baseline, before intervention
|
mean physical function
Time Frame: baseline, before intervention
|
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children.
It can be used with the general population and with individuals living with chronic conditions.
Scores are typically between 20-80, but may be 0-100.
Any result with higher a higher number is indicating higher physical function effect.
|
baseline, before intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 24, 2021
Primary Completion (Actual)
December 1, 2021
Study Completion (Actual)
December 1, 2021
Study Registration Dates
First Submitted
December 3, 2020
First Submitted That Met QC Criteria
December 3, 2020
First Posted (Actual)
December 4, 2020
Study Record Updates
Last Update Posted (Actual)
April 10, 2023
Last Update Submitted That Met QC Criteria
April 7, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- STUDY00005316
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
participant data will not be available for other researchers.
data is to remain in house at URMC.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ankle Pathology
-
Petr RoutnerRecruitingAnkle Injuries | Ankle Fractures | Ankle Sprains | Ankle Edema | Ankle ImpingementCzechia
-
Federal University of Minas GeraisCompletedAnkle Fractures | Achilles Tendon Rupture | Ankle Sprains | Ankle Dislocations | Ankle BruisesBrazil
-
Hadassah Medical OrganizationCompleted
-
Georgia State UniversityNational Athletic Trainers' Association Research & Education Foundation (NATA...CompletedChronic Ankle Instability | Ankle Sprains | Ankle RehabilitationUnited States
-
Peking University Third HospitalRecruitingAnkle Sprains | Hypermobility SyndromeChina
-
Investigación en Hemofilia y FisioterapiaCompleted
-
University of AlcalaCompleted
-
NYU Langone HealthCompletedAnkle FractureUnited States
-
Decathlon SEEFOR, FranceTerminatedAnkle Sprain 1St Degree | Ankle Sprain 2Nd Degree | Ankle Sprain 3Rd DegreeFrance
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States